sever
acut
respiratori
syndrom
sar
potenti
lethal
ill
caus
infect
newli
discov
coronaviru
caus
outbreak
infect
hong
kong
worldwid
world
health
organ
revis
case
fatal
ratio
previou
experi
vietnam
hong
kong
may
influenc
mean
fatal
rate
disproport
increas
patient
age
older
mani
therefor
age
doubt
function
independ
risk
factor
fatal
howev
inform
biochem
immunolog
marker
help
clinician
predict
advers
clinic
outcom
serum
total
lactat
dehydrogenas
ld
activ
alon
blood
leucocyt
lymphocyt
subset
report
decreas
respect
cohort
beij
howev
prognost
implic
thoroughli
investig
studi
conduct
assess
prognost
valu
paramet
sar
patient
met
modifi
case
definit
sar
admit
two
major
acut
hospit
hong
kong
march
may
includ
studi
two
major
acut
hospit
princ
wale
hospit
pwh
unit
christian
hospit
uch
hong
kong
pwh
locat
new
territori
east
region
initi
outbreak
affect
health
care
profession
uch
situat
kowloon
east
region
within
catchment
area
amoy
garden
commun
outbreak
case
clinic
case
definit
sar
fever
bodi
temperatur
higher
cough
short
breath
new
pulmonari
infiltr
chest
radiograph
either
histori
exposur
confirm
patient
sar
lack
respons
empir
antimicrobi
therapi
typic
atyp
pneumonia
includ
macrolid
fluoroquinolon
tetracyclin
patient
diagnos
subsequ
confirm
either
serolog
detect
antibodi
coronaviru
demonstr
use
polymeras
chain
reaction
techniqu
sar
patient
given
follow
treatment
accord
protocol
hong
kong
first
day
admiss
ribavirin
given
either
oral
g
three
time
daili
load
dose
g
intraven
mg
everi
h
complet
cours
levofloxacin
cefotaxim
supplement
cover
bacteri
chest
infect
persist
fever
third
day
admiss
mainten
steroid
therapi
would
start
use
either
oral
prednisolon
mg
intraven
hydrocortison
mg
everi
h
titrat
start
third
week
admiss
patient
clinic
deterior
includ
desatur
oxygen
satur
use
puls
oximetri
develop
new
infiltr
chest
radiograph
puls
steroid
use
methylprednisolon
g
daili
day
given
serial
ethylenediaminetetraacet
acid
edta
clot
blood
sampl
collect
daili
first
day
hospit
admiss
acut
diseas
gener
medic
ward
icu
applic
till
death
discharg
home
anoth
convalesc
hospit
edta
blood
sampl
use
assess
complet
blood
pictur
includ
total
differenti
leucocyt
count
blood
cell
counter
inc
miami
fl
usa
lymphocyt
subset
enumer
flow
cytometri
multitest
imk
kit
facscalibur
flow
cytomet
corp
san
jose
ca
usa
immun
fluoresc
reagent
contain
monoclon
antibodi
cluster
differenti
cd
antigen
includ
clone
total
lymphocyt
clone
lymphocyt
clone
lymphocyt
cytotox
lymphocyt
clone
ncam
natur
killer
cell
clone
b
lymphocyt
centrifug
clot
blood
sampl
g
min
sera
aliquot
within
cabinet
measur
serum
total
ld
activ
use
enzymat
assay
dp
modular
analys
roch
diagnost
corp
indianapoli
usa
patient
sera
peak
ld
activ
subject
isoenzym
studi
agaros
gel
electrophoresi
follow
densitometri
scan
paragon
electrophoresi
system
inc
la
ca
usa
isoenzym
activ
calcul
multipli
total
ld
activ
respect
scan
percentag
serum
cardiac
troponin
ctnt
concentr
measur
patient
use
concurr
serum
sampl
ld
isoenzym
determin
possibl
origin
elecsi
analys
roch
diagnost
corp
deriv
paramet
includ
blood
cell
count
ratio
isoenzym
ratio
comput
use
respect
measur
data
multipl
receiv
oper
characterist
roc
curv
comparison
nonparametr
test
appli
use
medcalc
programm
http
wwwmedcalcb
roc
curv
analysi
programm
choos
respect
valu
input
variabl
automat
fals
neg
fals
posit
rate
minim
posit
neg
likelihood
ratio
also
determin
chosen
valu
programm
confid
interv
central
distribut
auc
use
roc
analysi
sensit
specif
valu
median
variou
biochem
immunolog
marker
also
comput
programm
chosen
statist
signific
probabl
total
patient
includ
present
studi
patient
uch
patient
pwh
male
femal
age
year
median
rang
iqr
five
patient
pwh
given
ribavirin
puls
steroid
due
regress
fever
establish
treatment
protocol
oral
intraven
ribavirin
given
patient
respect
oral
prednisolon
intraven
hydrocortison
given
patient
respect
total
patient
receiv
puls
steroid
median
cumul
dose
puls
methylprednisolon
g
iqr
total
patient
admit
icu
die
total
fatal
patient
die
icu
die
gener
medic
ward
detail
patient
demograph
therapeut
intervent
advers
clinic
outcom
summar
tabl
multipl
roc
curv
comparison
predict
advers
clinic
outcom
summar
tabl
age
found
independ
prognost
indictor
predict
death
auc
confid
interv
ci
predict
admiss
icu
auc
ci
whilst
serum
total
ld
activ
could
achiev
auc
ci
predict
death
found
best
biochem
prognost
indic
predict
death
auc
ci
activ
u
statist
signific
differ
auc
death
predict
serum
activ
compar
rest
ld
isoenzym
ratio
ctnt
concentr
blood
haemoglobin
concentr
total
leucocyt
lymphocyt
count
multipl
roc
curv
comparison
predict
death
present
fig
predict
admiss
icu
natur
killer
cell
count
b
lymphocyt
promis
immunolog
prognost
indic
auc
ci
ci
ci
ci
respect
superior
age
serum
total
ld
ld
isoenzym
activ
blood
haemoglobin
concentr
total
leucocyt
lymphocyt
count
well
ratio
predictor
admiss
icu
statist
signific
differ
auc
multipl
roc
curv
comparison
predict
death
present
fig
prognost
signific
serum
total
ld
sar
repeatedli
demonstr
sever
studi
hong
kong
prompt
us
investig
prognost
signific
ld
isoenzym
present
studi
ld
cytoplasm
enzym
ubiquit
tissu
distribut
mammalian
speci
human
ld
tetram
molecular
weight
kda
sizeabl
molecul
releas
extracellular
fluid
cytoplasm
membran
must
due
either
normal
cellular
turnov
apoptosi
tissu
destruct
acut
myocardi
infarct
ami
five
ld
isoenzym
found
human
serum
differ
tissu
predomin
myocardium
contribut
total
ld
activ
blood
erythrocyt
contribut
two
major
sourc
found
human
serum
elev
serum
total
ld
activ
found
major
contributor
compar
ld
isoenzym
evidenc
high
prognost
valu
predict
death
whilst
full
evalu
five
ld
isoenzym
requir
electrophoresi
routin
monitor
serum
simpl
total
ld
assay
easili
perform
autom
analysi
laboratori
increas
serum
sar
thought
origin
blood
erythrocyt
bodi
tissu
myocardium
evidenc
sampl
cardiac
troponin
ctnt
ami
amongst
patient
rais
serum
ctnt
concentr
eight
document
relat
cardiovascular
system
includ
hypertens
chronic
rheumat
heart
diseas
congest
heart
failur
atrial
fibril
complet
heart
block
previou
histori
ami
diabet
mellitu
serum
ctnt
concentr
subject
roc
curv
analysi
serum
activ
auc
predict
death
ci
statist
differ
auc
serum
ctnt
concentr
activ
predict
death
tabl
moreov
exclus
patient
n
rais
serum
ctnt
concentr
repeat
analysi
data
set
still
show
serum
activ
could
predict
death
auc
ci
activ
remain
u
sensit
ci
specif
ci
posit
neg
likelihood
ratio
respect
addit
signific
differ
ratio
deceas
survivor
p
poor
predictor
death
auc
ci
ratio
increas
myocardi
damag
find
make
origin
serum
myocardium
even
unlik
increas
serum
ld
activ
postul
result
massiv
tissu
destruct
acut
phase
infect
immun
hyperact
support
hypothesi
group
recent
shown
cytokin
chemokin
storm
signific
elev
cell
cytokin
inflammatori
cytokin
interleukin
il
neutrophil
chemokin
monocyt
chemoattract
earli
phase
infect
contrast
sar
exist
previou
report
massiv
tissu
destruct
increas
serum
ld
activ
influenza
viru
infect
although
infect
caus
lymphopenia
latter
absenc
massiv
tissu
destruct
could
account
tissu
tropism
avian
flu
viru
toward
lung
parenchyma
predominantli
diminish
cytokin
product
major
contributor
elev
ld
sar
patient
like
former
also
origin
tissu
destruct
howev
abundantli
distribut
erythrocyt
haemolyt
effect
ribavirin
exclud
anoth
possibl
caus
center
diseas
control
prevent
cdc
indic
onlin
may
preliminari
vitro
experi
suggest
ribavirin
inhibit
growth
spread
new
coronaviru
test
howev
time
sar
outbreak
hong
kong
known
effect
antivir
agent
definit
uneth
withhold
antivir
treatment
avail
requir
use
continu
massiv
puls
corticosteroid
therapi
time
later
knowl
et
al
report
use
ribavirin
associ
signific
haemolyt
anaemia
prolong
hospit
stay
studi
efficaci
toxic
ribavirin
therapi
sar
requir
elucid
random
clinic
trial
marker
lymphocyt
subset
includ
cell
count
promis
indic
predict
admiss
icu
repres
lymphocyt
name
total
cytotox
lymphocyt
well
natur
killer
cell
much
involv
develop
humor
cytotox
immun
viral
infect
mark
reduct
absolut
count
could
possibl
due
direct
viral
cytotox
steroid
therapi
immunolog
marker
start
rise
trough
valu
suppress
cell
count
may
implic
pathophysiolog
sar
acquir
immunodefici
syndrom
aid
select
popul
cell
attack
destroy
human
immunodefici
viru
hiv
exist
publish
recommend
measur
cell
count
cdc
monitor
diseas
cours
therapeut
efficaci
hiv
infect
aid
initi
outbreak
sar
pwh
encount
difficulti
alloc
limit
number
icu
bed
sar
patient
requir
icu
care
could
high
therefor
measur
immunolog
marker
use
plan
manag
sar
patient
particular
estim
icu
bed
requir
conclus
serum
activ
found
good
prognost
indic
predict
death
patient
sar
compar
serum
total
ld
activ
haemoglobin
concentr
leucocyt
lymphocyt
count
releas
could
possibl
blood
erythrocyt
bodi
tissu
myocardium
routin
monitor
serum
simpl
total
ld
assay
close
monitor
sar
patient
use
serum
perform
ensur
prompt
manag
blood
natur
killer
cell
count
found
good
prognost
indic
predict
admiss
icu
patient
sar
compar
age
leucocyt
count
ld
isoenzym
suppress
natur
killer
cell
count
also
implic
pathophysiolog
sar
prepar
admiss
icu
could
plan
ahead
patient
suppress
lymphocyt
subset
awar
conflict
interest
